The upward rally in Healthcare sector stock Paradigm Biopharmaceuticals Limited (ASX: PAR) is hard to go unnoticed. The stock has returned as massive as 556.67% yields in the past 12 months, incorporating a positive price momentum of 103.09% over the past three months.
Paradigm is a disruptor in the anti-inflammatory drug market, as it has achieved significant success in the treatment of diseases involving inflammation, which remains a great challenge in modern medicine. The company focuses on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of injuries and conditions relating to inflammation.
Its leading clinical indications include treating bone marrow edema, which is an increasingly recognised pathological change in bone, and a substantial contributor to pain and symptoms in Osteoarthritis and acute joint injury.
In the highly-attractive Biopharma industry, Paradigm has undoubtedly seized the investors’ attention with lucrative 432.43% returns since its listing in 2015. These bullish market trends seem to be underpinned by the pioneering pre-clinical work on the effectiveness of the drug, Pentosan Polysulfate Sodium (PPS) in the field of mucopolysaccharidosis (MPS) and lysosomal storage diseases.
Its clinical trials address the severe unmet needs of the progressive rare disease, MPS. The company believes that these drugs have the potential to tap the approximately US$1.4 billion per annum market, as there are no appropriate standards of care in treating pain associated with musculoskeletal issues and joint inflammation.
Paradigm’s proposal for forthcoming MPS clinical trial has been well in line, with the evidence presented from clinicians regarding the need for a product to assist, with pain associated with musculoskeletal pain and dysfunction. This has led to preliminary discussions around the proposed clinical trial study design and site locations for the multi-centre study across the USA, Australia and Europe.
Inflammation, adverse tissue remodeling or tissue damage are the biological processes which eventually lead to the development of chronic diseases such as heart failure, osteoarthritis and respiratory diseases like asthma and hay fever.
The company concluded that clinical trials have proven the PPS’ capability in resulting a significant reduction of urinary GAG excretion, and an improvement of joint and mobility pain in a well-tolerated and safe setting. Paradigm believes injectable pentosan polysulfate sodium (iPPS) could have strong commercial success, based on recent clinical trials that have demonstrated its positive impact on pain, and physical function in patients suffering from MPS while maintaining an excellent safety profile, with no serious adverse events reported.
Paradigm reported a loss for the period ended 31 December 2018 of $4,400,269, compared to $3,573,244 in the previous corresponding period. However, the Group has managed to achieve a decent top-line growth reporting 25.99% increase in revenue to $28,140 during the half-year ended 31 December 2018.
As at 31 December 2018, the Group’s cash balance stood at $9.93 million.
PAR last traded at A$1.970 with a market capitalisation of A$276.39 million as on 5 April 2019.